NASDAQ: LEXXLexaria Bioscience Corp Stock
$1.21-0.25 (-17.12%)
Updated Sep 17, 2025
LEXX Price
$1.21
Fair Value Price
N/A
Market Cap
$23.67M
52 Week Low
$0.78
52 Week High
$3.39
P/E
-1.81x
P/B
4.26x
P/S
30.3x
PEG
N/A
Dividend Yield
N/A
Revenue
$615.92k
Earnings
-$11.39M
Gross Margin
99.6%
Operating Margin
-1,849.39%
Profit Margin
-1,849.4%
Debt to Equity
0.28
Operating Cash Flow
-$10M
Beta
0.78
Next Earnings
Oct 29, 2025
Ex-Dividend
N/A
Next Dividend
N/A
LEXX Overview
Lexaria Bioscience Corporation is a biotech company developing a drug delivery technology, DehydraTECH, that improves the way active pharmaceutical ingredients enter the bloodstream. Dehydra being evaluated for orally administered anti-viral drugs and non-steroidal anti-inflammatory drugs. Lexaria Bioscience was incorporated in 2004 and is headquartered in Kelowna, British Columbia, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LEXX's potential to beat the market
- LEXX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LEXX
RankedUnranked of 479
RankedUnranked of 479
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.05 | A | |
| $7.70 | A | |
| $34.22 | A |
Be the first to know about important LEXX news, forecast changes, insider trades & much more!
LEXX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LEXX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LEXX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LEXX is good value based on its book value relative to its share price (4.26x), compared to the US Biotechnology industry average (4.69x)
P/B vs Industry Valuation
LEXX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LEXX due diligence checks available for Premium users.
Valuation
LEXX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.81x
Industry
-97.28x
Market
37.36x
LEXX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.26x
Industry
4.69x
LEXX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LEXX's financial health
Profit margin
Revenue
$174.0k
Net Income
-$3.8M
Profit Margin
-2,177.6%
LEXX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LEXX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.7M
Liabilities
$1.6M
Debt to equity
0.28
LEXX's short-term assets ($5.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LEXX's short-term assets ($5.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LEXX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
LEXX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.6M
Investing
-$19.4k
Financing
$1.7M
LEXX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LEXX vs Biotech Stocks
Lexaria Bioscience Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.